Status:
COMPLETED
Clinical Study of 18F -FAPI-RGD in Renal Tumor
Lead Sponsor:
Sichuan Provincial People's Hospital
Conditions:
Renal Tumor
Eligibility:
All Genders
18+ years
Brief Summary
The goal of this observational study is to learn about the value of 18F-FAPI-RGD PET/CT imaging in Renal Tumor. Participants will undergo clinical evaluation and 18F-FAPI-RGD PET/CT examination.
Detailed Description
Early detection, accurate diagnosis and staging are the keys to effective treatment of kidney cancer patients.Pathological diagnosis is still the gold standard, but renal perforation is invasive exami...
Eligibility Criteria
Inclusion
- Age 18 and above
- No gender difference
- Patients who have been diagnosed with, or are clinically highly suspected of, renal tumors and have had no other treatment within 3 months
Exclusion
- Patients with a second primary tumor
- Pregnant or breastfeeding
- Severe liver or kidney disease
- Claustrophobia or other PET/CT scan contraindications
Key Trial Info
Start Date :
June 20 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 20 2024
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT05976607
Start Date
June 20 2023
End Date
February 20 2024
Last Update
April 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Departments of Nephrology, Sichuan Provincial People's Hospital
Chengdu, Sichuan, China, 610072